“`html
Regeneron Pharmaceuticals, Inc. (Symbol: REGN) shares have surpassed the average 12-month analyst target of $696.42, currently trading at $698.20 per share. Analysts will need to decide whether to downgrade the stock or adjust their target price higher following this increase.
A total of 12 analysts contribute to the average target, with estimates ranging from a low of $575.00 to a high of $843.00, resulting in a standard deviation of $82.439. Currently, analysts rate the stock with 7 strong buys, 5 holds, and 1 sell, with an average rating of 2.0 on a scale where 1 is “Strong Buy” and 5 is “Strong Sell”.
“`
